Black Diamond Therapeutics

BDTX · NASDAQ

$2.07+$0.26 (+14.36%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $1.81

About BDTX

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Employees: 21
Headquarters: Cambridge, Massachusetts
Listed: Jan 30, 2020
Sector: Health Care
Industry: Biotechnology
Website: blackdiamondtherapeutics.com

Leadership

Black Diamond Therapeutics executives
Name	Title	Since	Age
Mark Velleca	—	2021	61
Elizabeth Buck	—	—	50
Erika Jones	—	—	40
Brent Hatzis-Schoch	—	—	60
Melanie Morrison	—	—	50
Sergey Yurasov	—	—	56
Samarth Kulkarni	—	—	46
Ali Behbahani	—	—	49
Shannon Campbell	—	—	59
Kapil Dhingra	—	—	65
Garry Menzel	—	—	60
Prakash Raman	—	—	55

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Black Diamond Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
OpenEye Scientific Software, Inc.	Supplier and customer	US	—

Similar companies

Companies in the same industry as Black Diamond Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.